More than half of all rectal cancers are T3 lesions, but they are classified as a single-stage category.
T he current TNM staging system has been regarded as a standard staging system for colorectal cancer ever since its introduction in 1987 by the American Joint Committee on Cancer and the International Union Against Cancer (UICC) owing to its superb reflection of prognosis. The depth of infiltration of primary tumor (T classification) and nodal status (N classification) were known as important prognostic factors for local recurrence and distant metastasis after surgery in patients with colorectal cancer. In the case of rectal cancer, some authors reported a prognostic influence of the mesorectal infiltration depth and have suggested that this parameter should be included in therapeutic decision making. [1] [2] [3] [4] [5] [6] [7] In 1993, the UICC proposed optional cutoff points for mesorectal extension in the context of pT3 and pT4 tumors. 8 Thereafter, several studies have described prognostic heterogeneity in patients with T3 rectal cancer with different prognostic cutoff points to subdivide the mesorectal extension depth (MED). Those studies used various prognostic cutoff points such as 2 mm, 2 3 mm, 5,9 4 mm, 4,6,7,10,11 5 mm, [12] [13] [14] and 6 mm. 1 On the Surveillance, Epidemiology, and End Results (SEER) database analysis, a clear difference in survival rates was found for patients with stage II rectal cancer (T4aN0, 55.7%; T4bN0, 44.7%) when the T4 tumors were subdivided into T4a and T4b according to the invasion or adhesion to adjacent organs or structures. 15 Subsequently, these expanded outcomes based on SEER rectal and colon cancer database analysis have been reflected in the seventh edition of the TNM staging system and changed the process of substaging stages II and III. However, these subdivided T4 tumors, which account for only 14.3% of the entire colorectal cancer and T3 tumors that account for more than 60% on the SEER database, were classified as a single-stage disease. Furthermore, the reliability of several cutoff points for stratifying the mesorectum in T3 tumors remains controversial. The aim of present study was to investigate the prognostic significance of the MED in T3 rectal cancer .   TABLE 1. T3 subclassification by Hermaneck et al 8   T3 classification   pT3a  Minimal  Tumor invades through the muscularis propria into the subserosa into nonperitonealized  pericolic or perirectal tissues not >1 mm beyond the outer border of muscularis  propria  pT3b Slight Tumor invades through the muscularis propria into the subserosa into nonperitonealized pericolic or perirectal tissues >1 mm but not >5 mm beyond the outer border of muscularis propria pT3c
Moderate Tumor invades through the muscularis propria into the subserosa into nonperitonealized pericolic or perirectal tissues >5 mm but not >15 mm beyond the outer border of muscularis propria pT3d
Extensive Tumor invades through the muscularis propria into the subserosa into nonperitonealized pericolic or perirectal tissues >15 mm beyond the outer border of muscularis propria 
MATERIALS AND METHODS

Patients and Surgical Treatments
The study was performed in accordance with the guidelines of our institutional review board, which deemed that informed consent was not required. We retrospectively studied 291 patients with T3 rectal cancer who underwent a curative-intent surgery between January 2003 and December 2009 at Seoul National University Hospital. All patients had primary rectal adenocarcinoma without any evidence of distant metastasis, and located within 15 cm from the anal verge. A standardized total mesorectal excision (TME) technique including high ligations of the inferior mesenteric vessels was used in all patients. For patients who underwent preoperative chemoradiotherapy (CRT), surgical resection was scheduled between 6 and 8 weeks after completion of CRT.
Preoperative CRT and Adjuvant Therapy
Radiotherapy was delivered to the whole pelvis at a dose of 45 Gy in 25 fractions, followed by a boost of 5.4 Gy to the primary tumor in 3 fractions over 5.5 weeks. One of the following preoperative chemotherapeutic regimens was delivered concurrently with radiotherapy: 1) 5-fluorouracil (5-FU) (2 cycles of bolus intravenous 5-FU 500 mg/m 2 per day for 3 days in the first and the fifth weeks of radiotherapy); 2) capecitabine (oral administration of capecitabine 1650 mg/m 2 twice daily during radiotherapy with weekend breaks). Postoperative adjuvant chemotherapy was started in patients with stage II and III disease within 3 to 4 weeks after surgery. The regimen is one of following: 1) FL 2 . A, Disease-free survival rates according to subdivision of mesorectal extension depth (MED) are illustrated. There was no significant difference in 5-year disease-free survival rate between T3a/T3b (p = 0.35) and T3c/T3d (p = 0.37). B, Disease-free survival rates in the patients with reclassifying with the use of a MED cutoff point of 5 mm are shown.
(6 cycles of 5-FU 375 mg/m 2 per day and leucovorin 20 mg/m 2 per day on days 1-5 every week); 2) FOLFOX (intravenous oxaliplatin (85 mg/m 2 per day) and leucovorin (400 mg/m 2 per day) on the first day, bolus intravenous 5-FU (400 mg/m 2 per day) on the first day, then continuous infusion of 1200 mg/m 2 per day for 2 days); 3) capecitabine (oral administration of capecitabine 2000-2500 mg/m 2 per day in 2 divided doses, days 1-14 with a 7-day rest, repeat every 3 weeks). Postoperative CRT protocol was identical to that of preoperative CRT.
Measurement of MED
T3 tumors were stratified according to the T3 subclassification proposed by Hermaneck 8 (Table 1) . It was subdivided on the basis of the histologic measurement of the maximum depth of invasion beyond the outer border of the muscular layer. Two specialized GI pathologists analyzed the depth of tumor invasion by dividing the tumor at the deepest invasion spot grossly into 4 sections in the form of a cross. For the depth inspection, they put at least 4 sections, and for the inspection of the entire tumor, they put 2 additional sections making at least 6 sections. Hematoxylin-and-eosin-stained sections are presented in Figure 1 .
When the outer border of the muscular layer was completely identifiable (sometimes identifiable as fragments of muscle), the distance from the outer border of the muscular layer to the deepest part of the invasion was measured. If the outer border was not clear, we checked the outer border at both ends of tumor where it was clear and drew a tentative line considering it as the outer border of muscle layer. For a separate mesorectal tumor nodule to be recognized as tumor deposit, it had to be large enough to be recognized as a lymph node and freely movable and not continuously connected to the main mass.
If it was very small and closely located to the main mass, it was considered as a tumor invasion rather than as a tumor deposit.
Statistical Analysis
The Kaplan-Meier method was used for the univariate analysis of the prognostic value of sex, age category, subdivided T3 category, lymph node involvement, tumor differentiation, angiolymphatic invasion, circumferential resection margin, and preoperative CRT. The Cox regression analysis was used to analyze the independent prognostic factors for recurrence-free survival. Statistical analyses were performed by using SPSS version 19 (IBM Inc, Somers, NY).
RESULTS
Clinicopathological Characteristics of Patient
The clinicopathological characteristics of 291 patients (214 men (73.5%), mean age = 60.4 ± 11.5 (range, 23-86) years) are shown in Disease-free survival rates according to MED were 86.5% in T3a, 74.2% in T3b, 58.3% in T3c, and 29.0% in T3d ( Fig. 2A) . The difference was not statistically significant between T3a and T3b, or between T3c and T3d. However, when recategorized as T3ab (MED ≤ 5 mm) and T3cd (MED > 5 mm), the 5-year disease-free survival rate of patients with T3ab rectal cancer was significantly higher than that of patients with T3cd (77.6% vs 55.2%, p < 0.001) ( Fig. 2B) . On univariate analysis, factors affecting the recurrence were preoperative CEA level ≥5 ng/mL, the status of lymph node metastasis, and MED >5 mm ( Table 3 ). Multivariate analysis showed that the lymph node metastasis (HR 3.347, 95% CI 1.834-6.566, p < 0.001), preoperative CEA level ≥5 ng/mL (HR 3.347, 95% CI 1.620-4.226, p < 0.001) and MED >5 mm (HR 1.661, 95% CI 1.013-2.725, p = 0.044) were independent factors for recurrence.
Prognostic Factors for Recurrence in Patients Treated With or Without Preoperative CRT
Univariate and multivariate regression analyses showed that the lymph node metastasis was the most powerful independent risk factor followed by the preoperative CEA level for postoperative recurrence in patients with T3 rectal cancer without preoperative CRT (Table 4 ). In these patients, although MED was statistically significant on the univariate analysis, it was not statistically significant on the multivariate analysis.
Preoperative CRT was delivered to 91 patients. Univariate and multivariate regression analyses showed that MED (HR 2.950, 95% CI 1.085-8.043, p = 0.04) and preoperative CEA level (HR 3.095, 95% CI 1.112-8.611, p = 0.03) were the independent risk factors in these patients. In this subgroup, nodal metastasis did not affect recurrence ( Table 5 ). In addition, analysis of patients with ypT3 rectal cancer according to MED and lymph node status showed lower 5-year survival rate of the T3cdN− group than that of the T3abN+ group (56.3% vs 79.3%, p = 0.27) ( Table 6 , Fig. 3) 
DISCUSSION
An accurate staging system to categorize patients into relatively homogeneous groups according to their prognosis is crucial because these groups enable clinicians to provide a tailored adjuvant therapy or surveillance to patients. The current TNM staging system was refined based on several studies identifying prognostic factors for survival and local or distant recurrence. The local extent of the primary tumor, lymph node metastases (pT and pN category according to the TNM staging system of the UICC/American Joint Committee on Cancer), angiolymphatic invasion, perineural invasion, and preoperative CEA level were found to have prog-nostic impact based on multiple trials. In addition, the prognostic significance of the MED in rectal cancer was advocated in several articles. [1] [2] [3] [4] [5] 11 Cawthorn et al 4 demonstrated that the patients with mesorectal extension of more than 4 mm had lower overall survival rate (<4 mm; 55% vs ≥4 mm; 25%, p < 0.001), but their study had some limitations in that they included the patients with rectal cancer without mesorectal invasion (stage I) and those who had undergone palliative surgery.
For the cutoff value of 3 mm as an independent prognostic factor, the results were inconsistent among authors. 5, 9 The aforementioned studies were conducted in a single institute, but Merkel et al 12 analyzed the Erlangen Registry for Colo-Rectal Carcinomas and the Study Group for Colo-Rectal Carcinoma data. They demonstrated that the 5-year disease-free survival rate was significantly higher in tumors with MED ≤5 mm, compared with tumors with MED >5 mm (85.4% vs 54.1%, p < 0.001) in the Erlangen Registry for Colo-Rectal Carcinomas data, but this result could not be reproduced in the Study Group for Colo-Rectal Carcinoma data. Miyoshi et al 1 determined the optimal cutoff point of 6 mm by using statistical analysis and advocated that the 5-year recurrence-free survival rate in the patients with MED <6 mm was higher (69% vs 55%, p < 0.05). They measured actual values and established the cutoff point in the first data set and validated the prognostic impact of the MED of 6 mm in the second data set.
Recently, Shirouzu et al 7 and Akagi et al 10 analyzed the database from the Study Group of the Japanese Society for Cancer of the Colon and Rectum to determine the optimal cutoff depth of mesorectal invasion for predicting the clinical oncologic outcome in patients with T3 rectal cancer. They also determined the optimal cutoff point statistically, but the value was different from that of Miyoshi et al. 1 They also advocated that the independent prognostic factors for recurrence-free survival in patients with stage T3 rectal cancer were lymph node metastasis (HR 2.70, 95% CI 2.070-3.525), depth of mesorectal extension, histologic grade (HR 1.41, 95% CI 1.084-1.833), and lymphatic invasion (HR 1.44, 95% CI 1.135-1.838). However, in these studies, none of the patients received preoperative radiotherapy or neoadjuvant chemotherapy before operative management, and more than half of the patients had undergone prophylactic lateral pelvic lymph node dissection. These clinical sets of patients are currently unusual in countries other than Japan.
In the present study, we confirmed that MED was one of the independent prognostic factors in patients with T3 rectal cancer, together with nodal status and CEA level, which are already well-known prognostic factors for colorectal cancer. This study included 91 patients who received preoperative CRT. On subgroup analysis of these patients, MED consistently had a significant impact on postoperative recurrence rate along with the CEA level, which had been suggested as a useful prognostic factor in patients treated with preoperative CRT by several previous studies. 1, 13, 14, 16 For T3 patients as a whole or T3 patients without preoperative CRT, lymph node metastasis was clearly the most important prognostic factor. However, interestingly, nodal status was not a significant prognostic factor for ypT3 rectal cancer. It is well known that radiotherapy or CRT has an involutional effect on lymphatic tissues, and this was reflected as decreased number of retrieved lymph nodes in patients treated with preoperative CRT. 17 It can be hypothesized that this involutional effect and nodal downstaging by preoperative CRT might obtund the prognostic impact of lymph node metastasis. So far, most studies on the prognostic impact of the MED in T3 rectal cancer included patients who did not receive preoperative CRT, with the exception of the study by Picon et al. 5 However, they argued that the microscopic perirectal fat invasion with a cutoff of 3 mm could not predict the oncologic outcome, but the analysis was not done in subgroup of ypT3 rectal cancer. This study is meaningful in that the current study identified the prognostic significance of MED not only in all T3 rectal cancers, but also in ypT3 rectal cancers. FIGURE 3 . Disease-free survival rates according to MED and nodal status are shown. In each of ypT3ab and ypT3cd rectal cancer group, there were no significant differences in the 5-year diseasefree survival rate according to the nodal status (p = 0.35, p = 0.71). Despite the lymph node metastasis, the survival rate of ypT3abN+ patients was higher than that of T3cdN− patients (79.3% vs 56.2%, p = 0.27).
However, there are 2 limitations in this study. One is that the specimens were examined by routine methods rather than by whole-mount section by the pathologists. This may compromise the accuracy of invasion depth assessment to a certain extent, because the use of whole-mount section would have provided the most accurate depth of invasion. Another limitation is that this study lacks identification of TME quality. Plane of surgery has emerged as a significant prognostic factor affecting oncologic outcomes in rectal cancer surgery, and the importance of the pathologic report about quality of TME has been highlighted recently. However, most of the patients in our study did not have information on the plane of surgery achieved. Leonard et al 18 dictated that the quality of TME shows heterogeneity between surgeons, and the ability of the surgeon to stay in the mesorectal plane is important in determining the quality of TME. In fact, all the operations included in our study were performed by 3 highly experienced surgeons who have performed thousands of colorectal cancer surgeries. The mesorectal quality of our practice was also demonstrated in our randomized prospective trial (COREAN trial), 19 which compared laparoscopic and open TME after preoperative CRT. Some of the cases in the present study were also enrolled in the COREAN trial. In that trial, the macroscopic TME quality was evaluated. For open surgery (n = 170), the percentage of complete, nearly complete, and incomplete was 74.7%, 13.5%, and 6.5%. For laparoscopic surgery (n = 170), the percentage was 72.4%, 19.4%, and 4.7%. These results were comparable or somewhat superior to other previous studies. [20] [21] [22] 
CONCLUSION
The depth of mesorectal extension >5 mm is a significant prognostic factor in patients with T3 rectal cancer. Especially in patients who received preoperative CRT, the depth of mesorectal extension may be more important than the nodal status in predicting the oncologic outcome. If these findings can be reproduced or validated in subsequent studies with larger numbers of cases, T3 substaging according to MED should be incorporated into the rectal cancer staging system.
